Clinical Trial Update: Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG) [Phase 2]

View source ↗

Summary

Phase IIA double-masked randomized sham-controlled trial of QPI-1007 given by a single intravitreal injection in acute primary angle-closure glaucoma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angle-closure Glaucoma

Drugs mentioned

• QPI-1007 (p53-targeted siRNA)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Glaucoma, Angle-closure, Primary, Acute | Phase 2 | Status: COMPLETED